Trump's blueprint forreducing drug costs states that price transparency is important inimplementing contracts under which insurers and pharmacy-benefitmanagers pay based on how well a drug works. (Photo:Shutterstock)
White House staff are reviewing a proposal that may requirepharmaceutical companies to be more transparent about their pricing, a keypiece of President Donald Trump's plan to lower drug costs.
The Office of Management and Budget has received a proposedregulation by the Department of Health and Human Services thatdeals with drug-pricing transparency in the U.S. Medicare and Medicaid systems. OMB typicallyreviews regulations before they're made public. The proposal,posted online Tuesday, was titled “Medicare and Medicaid Programs;Regulation to Require Drug Pricing Transparency.” Little otherinformation was made publicly available.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
